ATE522626T1 - Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken - Google Patents
Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrückenInfo
- Publication number
- ATE522626T1 ATE522626T1 AT09003559T AT09003559T ATE522626T1 AT E522626 T1 ATE522626 T1 AT E522626T1 AT 09003559 T AT09003559 T AT 09003559T AT 09003559 T AT09003559 T AT 09003559T AT E522626 T1 ATE522626 T1 AT E522626T1
- Authority
- AT
- Austria
- Prior art keywords
- expression
- methods
- htt
- preferentially suppress
- mutated huntingtin
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 230000014509 gene expression Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69507805P | 2005-06-28 | 2005-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE522626T1 true ATE522626T1 (de) | 2011-09-15 |
Family
ID=37461493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09003559T ATE522626T1 (de) | 2005-06-28 | 2006-06-28 | Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070161590A1 (de) |
| EP (4) | EP2062980B1 (de) |
| AT (1) | ATE522626T1 (de) |
| WO (1) | WO2007002904A2 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027980A1 (en) * | 2003-09-12 | 2005-03-31 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
| US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
| US9133517B2 (en) * | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
| EP2239328A3 (de) | 2005-08-18 | 2011-01-05 | Alnylam Pharmaceuticals Inc. | Verfahren und Zusammensetzungen zur Behandlung von neurologischen Erkrankungen |
| US9273356B2 (en) * | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
| EP2046993A4 (de) * | 2006-07-07 | 2010-11-17 | Univ Massachusetts | Rna-interferenzzusammensetzungen und verfahren zur behandlung von morbus huntington |
| WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
| JP2010533170A (ja) | 2007-07-12 | 2010-10-21 | プロセンサ テクノロジーズ ビー．ブイ． | 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子 |
| WO2009008727A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| JP2011510678A (ja) | 2008-02-08 | 2011-04-07 | プロセンサ ホールディング ビーブイ | Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段 |
| AU2009244013B2 (en) * | 2008-05-09 | 2015-06-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington's disease |
| US8679750B2 (en) | 2008-05-09 | 2014-03-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington'S disease |
| EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| CA2756670A1 (en) * | 2009-03-26 | 2010-09-30 | The Regents Of The University Of California | Mesenchymal stem cells producing inhibitory rna for disease modification |
| CN102459595A (zh) | 2009-04-24 | 2012-05-16 | 普罗森那技术公司 | 用于治疗dmd的包含肌苷的寡核苷酸 |
| EP2451461A4 (de) | 2009-07-06 | 2013-05-29 | Ontorii Inc | Neuartige nukleinsäure-prodrugs und verwendungsverfahren dafür |
| ES2733708T3 (es) * | 2010-02-08 | 2019-12-02 | Ionis Pharmaceuticals Inc | Reducción selectiva de variantes alélicas |
| JP6018506B2 (ja) | 2010-02-08 | 2016-11-02 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 対立遺伝子多様体の選択的低減 |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| US20140303235A1 (en) | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| EP4086347A3 (de) | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selektive antisense-verbindungen und verwendungen davon |
| EP3095459A4 (de) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| EP3095461A4 (de) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator |
| EP3094728B1 (de) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chirales design |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| AU2017220774B2 (en) * | 2016-02-15 | 2022-12-08 | Istituti Clinici Scientifici Maugeri Spa Sb | Method of allele specific silencing for the treatment of autosomal dominant Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) |
| EP3452596A4 (de) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | Oligonukleotidzusammensetzungen und verfahren dafür |
| US12275999B2 (en) | 2016-11-10 | 2025-04-15 | Talis Biomedical Corporation | Polynucleotides for the amplification and detection of chlamydia trachomatis |
| CN106884047B (zh) * | 2017-02-15 | 2021-03-23 | 济南大学 | 基于核酸适配体检测miRNA-155的方法 |
| US12264365B2 (en) | 2020-03-23 | 2025-04-01 | Talis Biomedical Corporation | Polynucleotides for amplification and detection of SARS-CoV-2 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| AU649074B2 (en) | 1990-10-12 | 1994-05-12 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5354326A (en) * | 1993-01-27 | 1994-10-11 | Medtronic, Inc. | Screening cable connector for interface to implanted lead |
| WO1995005864A1 (en) * | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
| US5849995A (en) * | 1993-09-27 | 1998-12-15 | The University Of British Columbia | Mouse model for Huntington's Disease and related DNA sequences |
| US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US6087171A (en) * | 1993-12-17 | 2000-07-11 | Spinal Cord Society | Method for inducing DNA synthesis in neurons |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
| US7069634B1 (en) * | 1995-04-28 | 2006-07-04 | Medtronic, Inc. | Method for manufacturing a catheter |
| AU5545596A (en) * | 1995-04-28 | 1996-11-18 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
| AU1430097A (en) | 1996-01-16 | 1997-08-11 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
| US7189222B2 (en) * | 1996-04-30 | 2007-03-13 | Medtronic, Inc. | Therapeutic method of treatment of alzheimer's disease |
| US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
| AU4266597A (en) * | 1996-09-11 | 1998-04-14 | General Hospital Corporation, The | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
| GB9706463D0 (en) * | 1997-03-27 | 1997-05-14 | Medical Res Council | A model of inflamation in the central nervous system for use in the study of disease |
| US5782892A (en) * | 1997-04-25 | 1998-07-21 | Medtronic, Inc. | Medical lead adaptor for external medical device |
| US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| US6187906B1 (en) * | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
| WO1999018792A1 (en) * | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
| US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
| US6436392B1 (en) * | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| US6245884B1 (en) * | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| US6313268B1 (en) * | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
| US6319905B1 (en) * | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
| US6310048B1 (en) * | 1999-12-09 | 2001-10-30 | St. Louis University | Antisense modulation of amyloid beta protein expression |
| US6468524B1 (en) * | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| US6551290B1 (en) * | 2000-03-31 | 2003-04-22 | Medtronic, Inc. | Catheter for target specific drug delivery |
| US6866859B2 (en) * | 2000-08-30 | 2005-03-15 | Biocoat Incorporated | Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties |
| US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| CA2477014A1 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of tnf and tnf receptor superfamily gene expression using short interfering nucleic acid (sina) |
| US20030224512A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
| US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| US20040023390A1 (en) * | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
| US20040241854A1 (en) * | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
| US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| US20050048641A1 (en) * | 2002-11-26 | 2005-03-03 | Medtronic, Inc. | System and method for delivering polynucleotides to the central nervous system |
| US7605249B2 (en) * | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| US20050079512A1 (en) * | 2003-02-26 | 2005-04-14 | Emerson Beverly M. | Methods of modulating gene expression |
| WO2005027980A1 (en) * | 2003-09-12 | 2005-03-31 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
| WO2005078096A2 (en) * | 2004-02-09 | 2005-08-25 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| US20050202075A1 (en) * | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
| US8240498B2 (en) | 2006-10-31 | 2012-08-14 | Crown Packaging Technology, Inc. | Resealable closure |
-
2006
- 2006-06-28 AT AT09003559T patent/ATE522626T1/de not_active IP Right Cessation
- 2006-06-28 WO PCT/US2006/025638 patent/WO2007002904A2/en not_active Ceased
- 2006-06-28 EP EP09003559A patent/EP2062980B1/de not_active Expired - Lifetime
- 2006-06-28 EP EP10012594A patent/EP2316967A1/de not_active Withdrawn
- 2006-06-28 EP EP06785990A patent/EP1896586A2/de not_active Withdrawn
- 2006-06-28 EP EP10012595.4A patent/EP2322657B1/de not_active Expired - Lifetime
- 2006-06-28 US US11/478,110 patent/US20070161590A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2322657A1 (de) | 2011-05-18 |
| EP2062980A2 (de) | 2009-05-27 |
| EP2322657B1 (de) | 2014-11-05 |
| EP2316967A1 (de) | 2011-05-04 |
| EP1896586A2 (de) | 2008-03-12 |
| WO2007002904A2 (en) | 2007-01-04 |
| EP2062980B1 (de) | 2011-08-31 |
| US20070161590A1 (en) | 2007-07-12 |
| EP2062980A3 (de) | 2009-08-26 |
| WO2007002904A3 (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007002904A3 (en) | Methods and sequences to preferentially suppress expression of mutated huntingtin | |
| WO2005081714A3 (en) | Use of interfering rna in the production of transgenic animals | |
| MX365031B (es) | Loci geneticos relacionados con la resistencia al carbon de la espiga del maiz. | |
| AU2001289600A1 (en) | Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription | |
| SG170819A1 (en) | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith | |
| WO2007134272A3 (en) | Humanized models via targeted mtagenesis with zinc finger nuclease | |
| WO2004066941A3 (en) | Expression profiles for colon cancer and methods of use | |
| CY1108944T1 (el) | Θεραπευτικη χρηση των tgf-βητα2 αντινοηματικων ολιγονουκλεοτιδιων | |
| ATE437962T1 (de) | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen | |
| CY1116175T1 (el) | Χρηση αναστολεων πεπτιδιου του μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν τα κυτταρα για τη θεραπευτικη αγωγη διαφορων καρδιαγγειακων νοσων | |
| WO2007087451A3 (en) | Compositions and methods for enhancing discriminatory rna interference | |
| DK2021472T3 (da) | Forbindelser og fremgangsmåder til modulering af genekspression | |
| WO2008005562A3 (en) | Rna silencing compositions and methods for the treatment of huntington's disease | |
| WO2005059108A3 (en) | Gene expression profiles and methods of use | |
| WO2010011283A3 (en) | Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases | |
| TNSN08252A1 (en) | Sirna anti myosine va et depigmentation de la peau | |
| WO2005032495A8 (en) | Gene expression profiles and methods of use | |
| US20170275622A1 (en) | ALTERATION OF NEURONAL GENE EXPRESSION BY SYNTHETIC piRNAs AND BY ALTERATION OF piRNA FUNCTION | |
| WO2009062042A3 (en) | Methods and compositions for improved cattle longevity and milk production | |
| ATE513929T1 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung | |
| WO2007058968A3 (en) | Gene expression profiles and methods of use | |
| WO2008052016A3 (en) | The sortilin-related receptor sorl1 is functionally and genetically associated with alzheimer's disease | |
| ATE510545T1 (de) | Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen | |
| WO2005113815A3 (en) | Polymorphisms in the fcgr2b promoter and uses thereof | |
| UA93658C2 (en) | Cell surface glycoprotein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |